Aims. To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine t wice daily and latanoprost once daily in primary open angl...Aims. To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine t wice daily and latanoprost once daily in primary open angle glaucoma or ocular hypertensive subjects. Methods. A prospective, double masked, active controlle d comparison in which qualified subjects had all glaucoma medicines discontinued for 1 month and then were randomized to either LTFC or brimonidine and latanopr ost concomitant therapy for 6 weeks. They were then switched to the other treatm ent regimen. The intraocular pressure (IOP) was measured at 0800, 1200, and 1600 h at baseline and at the end of Periods 1 and Period 2. Results. In 32 subjects , the diurnal curve of the untreated IOP of 26.0±3.4 decreased to 17.8±2.5 on LTFC and 17.2±2.8 mmHg on brimonidine and latanoprost (P=0.31). At 0800 and 160 0 h, the IOPs were statistically similar between the groups (P > 0.05). At 1200 h the latanoprost and brimonidine treatment IOP was statistically lower (16.2±3 .2) than LTFC (18.0±2.8 mmHg). However, the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve fo r each therapy (P < 0.05). Safety was similar between groups for both solicited and unsolicited side effects (P > 0.05). Conclusion. This study suggests that LT FC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline.展开更多
文摘Aims. To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine t wice daily and latanoprost once daily in primary open angle glaucoma or ocular hypertensive subjects. Methods. A prospective, double masked, active controlle d comparison in which qualified subjects had all glaucoma medicines discontinued for 1 month and then were randomized to either LTFC or brimonidine and latanopr ost concomitant therapy for 6 weeks. They were then switched to the other treatm ent regimen. The intraocular pressure (IOP) was measured at 0800, 1200, and 1600 h at baseline and at the end of Periods 1 and Period 2. Results. In 32 subjects , the diurnal curve of the untreated IOP of 26.0±3.4 decreased to 17.8±2.5 on LTFC and 17.2±2.8 mmHg on brimonidine and latanoprost (P=0.31). At 0800 and 160 0 h, the IOPs were statistically similar between the groups (P > 0.05). At 1200 h the latanoprost and brimonidine treatment IOP was statistically lower (16.2±3 .2) than LTFC (18.0±2.8 mmHg). However, the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve fo r each therapy (P < 0.05). Safety was similar between groups for both solicited and unsolicited side effects (P > 0.05). Conclusion. This study suggests that LT FC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline.
